Trial Profile
Observational study on Ibrutinib Compassionate use named patient program (NPP) in patients with relapsed or refractory chronic lymphocytic leukemia in Poland
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 14 Jul 2020
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Expanded access; Therapeutic Use
- 01 Jul 2020 Results published in the Anticancer Research
- 15 Sep 2016 New trial record